{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:44:24Z","timestamp":1789083864151,"version":"build-2803163510"},"reference-count":15,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>Mutations in genes encoding RNA splicing factors are common in patients with myeloid malignancies and chronic lymphocytic leukemia. In this commentary, we discuss key unanswered questions on the causal role of these mutations in blood cancers and precursor conditions as well as efforts to develop therapies targeting these high-frequency neomorphic mutations.<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-26-0047","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:31:54Z","timestamp":1776799914000},"page":"348-352","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outstanding Questions to Understand and Target Splicing Factor\u2013Mutant Blood Cancers"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7809-5888","authenticated-orcid":false,"given":"Maxim I.","family":"Maron","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center Molecular Pharmacology Program, Sloan Kettering Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-6171","authenticated-orcid":false,"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center Molecular Pharmacology Program, Sloan Kettering Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026050503062930200_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"2026050503062930200_bib2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ccell.2023.04.006","article-title":"Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population","volume":"41","author":"van Zeventer","year":"2023","journal-title":"Cancer Cell"},{"key":"2026050503062930200_bib3","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.1038\/s41467-024-52302-9","article-title":"Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis","volume":"15","author":"Uddin","year":"2024","journal-title":"Nat Commun"},{"key":"2026050503062930200_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"2026050503062930200_bib5","doi-asserted-by":"crossref","first-page":"116075","DOI":"10.1016\/j.celrep.2025.116075","article-title":"SUGP1 loss drives SF3B1 hotspot mutant missplicing in cancer","volume":"44","author":"Xing","year":"2025","journal-title":"Cell Rep"},{"key":"2026050503062930200_bib6","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.molcel.2024.04.006","article-title":"GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies","volume":"84","author":"Benbarche","year":"2024","journal-title":"Mol Cell"},{"key":"2026050503062930200_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","article-title":"Spliceosomal disruption of the non-canonical BAF complex in cancer","volume":"574","author":"Inoue","year":"2019","journal-title":"Nature"},{"key":"2026050503062930200_bib8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025029972","article-title":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability","author":"Sekrecki","year":"2026  26","journal-title":"Blood J"},{"key":"2026050503062930200_bib9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","article-title":"The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations","volume":"69","author":"Chen","year":"2018","journal-title":"Mol Cell"},{"key":"2026050503062930200_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-019-1650-0","article-title":"Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma","volume":"574","author":"Suzuki","year":"2019","journal-title":"Nature"},{"key":"2026050503062930200_bib11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-019-1651-z","article-title":"The U1 spliceosomal RNA is recurrently mutated in multiple cancers","volume":"574","author":"Shuai","year":"2019","journal-title":"Nature"},{"key":"2026050503062930200_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41525-022-00292-2","article-title":"PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2","volume":"7","author":"Bousquets-Mu\u00f1oz","year":"2022","journal-title":"NPJ Genom Med"},{"key":"2026050503062930200_bib13","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1101\/gr.246678.118","article-title":"RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing","volume":"29","author":"Dvinge","year":"2019","journal-title":"Genome Res"},{"key":"2026050503062930200_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41587-022-01224-2","article-title":"Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells","volume":"40","author":"North","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026050503062930200_bib15","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","article-title":"Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias","volume":"188","author":"Kim","year":"2025","journal-title":"Cell"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0047\/3769968\/bcd-26-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/348\/3783095\/bcd-26-0047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/348\/3783095\/bcd-26-0047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:06:32Z","timestamp":1777964792000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/3\/348\/784441\/Outstanding-Questions-to-Understand-and-Target"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0047","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}